(Total Views: 410)
Posted On: 09/16/2021 11:14:17 AM
Post# of 148892
I thought yesterday’s call was excellent and I am surprised (and a little disappointed) that the stock hasn’t risen more.
Sales in Philippines, while probably at a low price, will bring in revenue none the less. The hint of possible EUA will be big if it comes to fruition.
The Amerax issue regarding the missing sequences is annoying. Likely Cytodyn will need to pay all outstanding invoices before these will be forwarded.
Brazil is underway but is a bit longer to revenue. With 700k vials available for sale, it could be the bridge that we need to end dilution.
The really big news could be Nash if the result in Oct (probably really November) are positive.
The academic institution collaboration on cancer will also be interesting once announced especially if we hear what the financial arrangements are. The good news is that we are getting cancer interest which is amazing.
Hoping for a string finish to 2021 - the shots on goal are there.
IMO
Sales in Philippines, while probably at a low price, will bring in revenue none the less. The hint of possible EUA will be big if it comes to fruition.
The Amerax issue regarding the missing sequences is annoying. Likely Cytodyn will need to pay all outstanding invoices before these will be forwarded.
Brazil is underway but is a bit longer to revenue. With 700k vials available for sale, it could be the bridge that we need to end dilution.
The really big news could be Nash if the result in Oct (probably really November) are positive.
The academic institution collaboration on cancer will also be interesting once announced especially if we hear what the financial arrangements are. The good news is that we are getting cancer interest which is amazing.
Hoping for a string finish to 2021 - the shots on goal are there.
IMO
(3)
(0)Scroll down for more posts ▼
